Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(33%)
Results Posted
33%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_4
1
17%
Ph phase_1
1
17%
Ph early_phase_1
3
50%
Ph phase_2
1
17%

Phase Distribution

4

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
3(50.0%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (50.0%)
Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 41 (16.7%)

Trials by Status

completed350%
recruiting233%
terminated117%

Recent Activity

Clinical Trials (6)

Drug Details

Intervention Type
PROCEDURE
Total Trials
6